ADORA2A and Parkinson disease: It still remains to be tested if this A2AR-mediated control of synaptotoxicity in the context of the PD prodrome is similar to that observed in different brain areas through mechanisms that are still unclear [25], or if it might involve the ability of A2AR to control α-synuclein [32,80] and its impact on the function and viability of striatal synapses [78,79] or an A2AR-mediated control of cholinergic interneurons [92,93,94].